Robeco Institutional Asset Management B.V. Sells 4,493 Shares of Stryker Corporation $SYK

Key Points

• Robeco Institutional Asset Management B.V. trimmed its Stryker stake by 1.4%, selling 4,493 shares and retaining 328,309 shares worth about $115.39 million.
• Director Ronda E. Stryker sold 250,000 shares for roughly $90.73 million, cutting her position by 9.23%; company insiders now own about 4.60% of the stock.
• Stryker beat quarterly expectations with $4.47 EPS versus $4.40 and $7.17 billion revenue (up 11.4% YoY), and declared a $0.88 quarterly dividend ($3.52 annual, ~1.0% yield).

Robeco Institutional Asset Management B.V. lessened its stake in shares of Stryker Corporation (NYSE:SYK - Free Report) by 1.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 328,309 shares of the medical technology company's stock after selling 4,493 shares during the period. Robeco Institutional Asset Management B.V. owned 0.09% of Stryker worth $115,391,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Clayton Financial Group LLC bought a new position in Stryker during the 3rd quarter worth $26,000. United Financial Planning Group LLC bought a new position in Stryker during the 3rd quarter worth $27,000. Strive Asset Management LLC bought a new position in Stryker during the 3rd quarter worth $30,000. ANTIPODES PARTNERS Ltd bought a new position in shares of Stryker in the 3rd quarter valued at $34,000. Finally, Lavaca Capital LLC bought a new position in shares of Stryker in the 2nd quarter valued at $40,000. Institutional investors own 77.09% of the company's stock.

Stryker Trading Up 0.1%

NYSE SYK opened at $339.32 on Monday. The company has a quick ratio of 1.21, a current ratio of 1.89 and a debt-to-equity ratio of 0.66. Stryker Corporation has a twelve month low of $319.32 and a twelve month high of $404.87. The company has a market cap of $129.95 billion, a price-to-earnings ratio of 40.40, a price-to-earnings-growth ratio of 1.98 and a beta of 0.92. The business's fifty day moving average is $354.87 and its 200 day moving average is $360.39.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, beating the consensus estimate of $4.40 by $0.07. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The company had revenue of $7.17 billion for the quarter, compared to the consensus estimate of $7.12 billion. During the same quarter last year, the business posted $4.01 EPS. Stryker's revenue for the quarter was up 11.4% on a year-over-year basis. As a group, sell-side analysts expect that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. Stryker's dividend payout ratio (DPR) is 41.90%.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 250,000 shares of the firm's stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the sale, the director owned 2,457,331 shares of the company's stock, valued at $891,814,566.52. This trade represents a 9.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 4.60% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on SYK shares. Jefferies Financial Group reiterated a "buy" rating and issued a $465.00 price target on shares of Stryker in a research note on Wednesday, March 4th. Weiss Ratings reiterated a "hold (c+)" rating on shares of Stryker in a research note on Monday, December 22nd. UBS Group decreased their price target on Stryker from $400.00 to $380.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 17th. Citizens Jmp upgraded Stryker from a "market perform" rating to an "outperform" rating and set a $440.00 price target on the stock in a research note on Friday, December 19th. Finally, Truist Financial decreased their price target on Stryker from $400.00 to $392.00 and set a "hold" rating on the stock in a research note on Thursday, December 18th. Fourteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $423.22.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.